Cardiovascular Diagnostic Testing Market Statistics- 2030

Global cardiovascular diagnostic testing market was valued at $6,876.29 million in 2020, and is projected to reach $15,430.46 million by 2030, registering a CAGR of 8.3% from 2021 to 2030.Cardiovascular diseases (CVDs) are a group of disorders of the heart & blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one-third of these deaths occur prematurely in people under 70 years of age. They are the leading cause of morbidity and mortality in humans, and millions of individuals worldwide die from acute cardiovascular events every year. 

[COVIDIMPACTSTATEMENT]

Various laboratory developed tests as well as in vitro diagnostic tests are available for diagnostic and prognostic purposes. Cardiovascular diagnostics are the tests performed on patients for screening and monitoring of heart to diagnose any prevalent cardiac disorders. 

Get more information on this report : Request Sample Pages

Cardiovascular diagnostic testing can provide information regarding the electrical activity of the heart, heartbeat rhythm, how well blood is pumping through the heart’s chamber and valves, how easily blood is flowing through the coronary arteries to the heart muscle, and whether there are tumors or abnormalities in the structure of the cardiovascular system. Laboratory tests are used to detect the risk factors for heart diseases. These include detection of the fats, cholesterol and lipid components of blood including LDL, HDL, triglycerides. Blood sugar and glycosylated hemoglobin is measured for detection of diabetes. C-reactive protein is protein (CRP) and other protein markers like apolipoprotein A1 and B are used to detect inflammation that may lead to heart disease.

The factors contribute to the growth of the cardiovascular diagnostic testing market include, rise in geriatric population, increase in prevalence of cardiovascular diseases, and unhealthy diet & sedentary lifestyle. Moreover, technological advancements in the treatment and devices, introduction of developed treatment procedures boost the growth of the cardiovascular diagnostic testing market. On the contrary FDA regulation and guidance of laboratory developed tests (LDTs) and limited insurance coverage and high cost of devices used for the diagnostic purpose hinder the growth of the cardiovascular diagnostic testing market. 

Emerging economies in Asia-Pacific and LAMEA offer lucrative growth opportunities to cardiovascular diagnostic testing, owing to improvement in healthcare infrastructure in these regions and increase in demand for better healthcare services among the patient population. Novel diagnostic technologies are expected to be launched in this market, owing to progression in healthcare facilities and technological advancements. The purchasing power of people in various developing nations is increasing due to formulation of different healthcare policies. For instance, in January 2014, the World Economic Forum in its project paper, Health Systems Leapfrogging in Emerging Economies, stated that, one-third of the global health expenditure would be focused on the provision of healthcare services in the emerging markets by 2022.

Impact of COVID-19 Pandemic on Cardiovascular Diagnostic Testing Market (Pre and Post Analysis)

Coronavirus disease (COVID-19) was discovered in late December in the Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans. After its discovery in Wuhan, the disease has rapidly spread to other parts of the globe. This virus causes various symptoms in a patient; for instance, common symptoms include fever, dry cough, and fatigue. However, serious symptoms include difficulty in breathing or shortness of breath, chest pain or pressure, and loss of speech or movement.

Furthermore, the virus has high potential of lethality in the geriatric population. On March 11, 2020, the World Health Organization assessed that COVID-19 can be characterized as a pandemic. In addition, no drugs are currently licensed for the treatment of COVID-19 treatment or prevention. Thus, social distancing is observed as the most important measure to stop the spread of this disease. Furthermore, to maintain social distancing, various countries across the world have adopted nationwide lockdown. Although the COVID-19 pandemic continues to impact the growth of various industries, and the immediate impact of the outbreak varies from industry to industry.

The impact of COVID-19 pandemic is expected to remain positive for the cardiovascular disease testing market. Owing to increase in medical condition such as diabetes heart diseases among others which are more vulnerable to COVID-19. Also, patients with pre-existing heart disease are suffering from COVID-19 are more prone to heart attacks or develop congestive heart failure. According to the national health commission about 35% of the total patient diagnosed with COVID-19 are suffering from hypertension and 17% from heart disease. 

COVID-19 pandemic has highlighted the importance of reliable diagnostic tests and quick development of novel assays. Moreover, coronavirus infection also affects the inner surfaces of veins and arteries, which can cause blood vessel inflammation, damage to very small vessels and blood clots, all of which can compromise blood flow to the heart or other parts of the body. Severe COVID-19 is a disease that affects endothelial cells, which form the lining of the blood vessels. Therefore, timely diagnosis become utmost important if a person has pre-existing heart issues. 

Type Segment Review

By type, the cardiovascular diagnostic testing market can be categorized into laboratory developed test (lipoprotein test, angiotensin test, fibrinogen test, fibrinogen test, high-sensitivity C-reactive protein (hsCRP) and in vitro diagnostic test (electrocardiogram test, echocardiography test, and transesophageal echocardiogram test). The in vitro diagnostic test segment dominates the cardiovascular diagnostic testing market, owing to increase in demand for the non-invasive diagnostic techniques and technological advancements leading to replacement of old conventional devices with the new one.

[TYPEGRAPH]

Get more information on this report : Request Sample Pages

Panel Segment Review

By panel, the cardiovascular diagnostic testing market is studied across atherosclerotic cardiovascular disease (ASCVD) risk panel with score.

End User Segment Review

By end user, the cardiovascular diagnostic testing market is segmented into laboratory testing facilities, academic institutes, and point-of-care testing facilities. The laboratory testing facilities segment held the largest market share in 2020 and is expected to remain dominant during the forecast period because laboratory testing is more advanced, and is fully integrated with the technology necessary to ensure that results are accurate, analyzed, validated and recorded.

[ENDUSERGRAPH]

Get more information on this report : Request Sample Pages

Region segment review

North America is expected to maintain its dominance during the forecast period due to the three major countries of North America considered in the report include the U.S., Canada, and Mexico. North America is dominating the market of overall Cardiovascular diagnostic testing and expected to dominate throughout the forecast period. This is majorly attributed to rise in incidences of coronary diseases. The rise in number of heart ailments can be attributed to the prevalence of high blood pressure, high- and low-density Lipoprotein cholesterol, and smoking which is prevalent in this region.

[REGIONGRAPH]

Get more information on this report : Request Sample Pages

This report provides comprehensive competitive analysis and profiles of prominent cardiovascular diagnostic testing market players such as Abbott Laboratories, Becton, Dickinson and Company, bioMérieux, Inc., Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Perkinelmer Inc., Siemens AG, Thermo Fisher Scientific Inc., and Tosoh Corporation.

Cardiovascular Diagnostic Testing Market Research Study Key Benefits

• This report provides a detailed quantitative analysis of the current cardiovascular diagnostic testing market trends and forecast estimations from 2020 to 2030, which assists to identify the prevailing market opportunities. 
• An in-depth market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
• A comprehensive analysis of factors that drive and restrain the growth of the global is provided.
• The projections in this report are made by analyzing the current trends and future market potential from 2021 to 2030, in terms of value.
• An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
• Key market players within the cardiovascular diagnostic testing market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of the cardiovascular diagnostic testing market.

 Key Market Segments

• By Type
  • Laboratory Developed Test
  • In-Vitro Diagnostic Test
• By Panel
  • Atherosclerotic cardiovascular disease (ASCVD) risk panel with score
• By End User
  • Laboratory Testing Facilities
  • Academic Institutes
  • Point-of-care Testing Facilities
• By Region
  • North America
  • Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

 
Key Market Players

• Becton
• Abbott Laboratories
• Dickinson and Company
• bioMérieux, Inc.
• Siemens AG
• PerkinElmer, Inc.
• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd
• Danaher Corporation
• Tosoh Corporation
• Bio-Rad Laboratories, Inc.

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profile in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Porters five forces analysis

3.2.1.Top investment pockets

3.3.Top player positioning, 2020
3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Worldwide rise in geriatric population coupled with increasing prevalence of cardiovascular diseases
3.4.1.2.Initiatives to spread awareness among patients
3.4.1.3.Increasing Medical Technology Innovations

3.4.2.Restraints

3.4.2.1.Limited insurance coverage and high cost of devices
3.4.2.2.Changes in FDA regulation and guidance of LDTs

3.4.3.Opportunity

3.4.3.1.Improvement in healthcare infrastructure in emerging nations

3.4.4.Impact analysis

3.5.Analysis of COVID-19-Impact on the Market

CHAPTER 4:CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Laboratory developed test

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market share analysis, by country
4.2.4.Market size and forecast, by type

4.2.4.1.Lipoprotein Test

4.2.4.1.1.Market size and forecast

4.2.4.2.Angiotensin Test

4.2.4.2.1.Market size and forecast

4.2.4.3.Fibrinogen Test

4.2.4.3.1.Market size and forecast

4.2.4.4.Serum Uric Acid Test

4.2.4.4.1.Market size and forecast

4.2.4.5.High-sensitivity C-reactive protein (hs-CRP)

4.2.4.5.1.Market size and forecast

4.3.In-Vitro diagnostic test

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.3.4.Market size and forecast, by type

4.3.4.1.Electrocardiogram Test (ECG)

4.3.4.1.1.Market size and forecast

4.3.4.2.Echocardiography Test

4.3.4.2.1.Market size and forecast

4.3.4.3.Transesophageal Echocardiogram Test

4.3.4.3.1.Market size and forecast

4.3.4.4.Others

4.3.4.4.1.Market size and forecast

CHAPTER 5:CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY PANEL

5.1.Overview
5.2.Atherosclerotic Cardiovascular Disease (ASCVD) Risk Panel with Score (Quest Diagnostics)

5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Cardio IQ Revenue, 2020

CHAPTER 6:CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Laboratory testing facilities

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Academic Institutes

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Point-of-care testing facilities

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

CHAPTER 7:CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America market size and forecast, by Type
7.2.3.North America market size and forecast, by end user
7.2.4.Market size and forecast, by country

7.2.4.1.U.S.

7.2.4.1.1.U.S. Cardiovascular diagnostic testing market, by type
7.2.4.1.2.U.S. Cardiovascular diagnostic testing market, by end user

7.2.4.2.Canada

7.2.4.2.1.Canada Cardiovascular diagnostic testing market, by Type
7.2.4.2.2.Canada Cardiovascular diagnostic testing market, by end user

7.2.4.3.Mexico

7.2.4.3.1.Mexico Cardiovascular diagnostic testing market, by Type
7.2.4.3.2.Mexico Cardiovascular diagnostic testing market, by end user

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe market size and forecast, by Type
7.3.3.Europe market size and forecast, by end user
7.3.4.Market size and forecast, by country

7.3.4.1.Germany

7.3.4.1.1.Germany Cardiovascular Diagnostic Testing market, by Type
7.3.4.1.2.Germany Cardiovascular Diagnostic Testing market, by end user

7.3.4.2.France

7.3.4.2.1.France Cardiovascular Diagnostic Testing market, by Type
7.3.4.2.2.France Cardiovascular Diagnostic Testing market, by end user

7.3.4.3.UK

7.3.4.3.1.UK Cardiovascular Diagnostic Testing market, by Type
7.3.4.3.2.UK Cardiovascular Diagnostic Testing market, by end user

7.3.4.4.Italy

7.3.4.4.1.Italy Cardiovascular Diagnostic Testing market, by Type
7.3.4.4.2.Italy Cardiovascular Diagnostic Testing market, by end user

7.3.4.5.Spain

7.3.4.5.1.Spain Cardiovascular Diagnostic Testing market, by Type
7.3.4.5.2.Spain Cardiovascular Diagnostic Testing market, by end user

7.3.4.6.Rest of Europe

7.3.4.6.1.Rest of Europe Cardiovascular Diagnostic Testing market, by Type
7.3.4.6.2.Rest of Europe Cardiovascular Diagnostic Testing market, by end user

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific market size and forecast, by Type
7.4.3.Asia-Pacific market size and forecast, by end user
7.4.4.Market size and forecast, by country

7.4.4.1.Japan

7.4.4.1.1.Japan Cardiovascular Diagnostic Testing market, by Type
7.4.4.1.2.Japan Cardiovascular Diagnostic Testing market, by end user

7.4.4.2.China

7.4.4.2.1.China Cardiovascular Diagnostic Testing market, by Type
7.4.4.2.2.China Cardiovascular Diagnostic Testing market, by end user

7.4.4.3.India

7.4.4.3.1.India Cardiovascular Diagnostic Testing market, by Type
7.4.4.3.2.India Cardiovascular Diagnostic Testing market, by end user

7.4.4.4.Australia

7.4.4.4.1.Australia Cardiovascular Diagnostic Testing market, by Type
7.4.4.4.2.Australia Cardiovascular Diagnostic Testing market, by end user

7.4.4.5.South Korea

7.4.4.5.1.South Korea Cardiovascular Diagnostic Testing market, by Type
7.4.4.5.2.South Korea Cardiovascular Diagnostic Testing market, by end user

7.4.4.6.Rest of Asia-Pacific

7.4.4.6.1.Rest of Asia-Pacific Cardiovascular Diagnostic Testing market, by Type
7.4.4.6.2.Rest of Asia-Pacific Cardiovascular Diagnostic Testing market, by end user

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA market size and forecast, by Type
7.5.3.LAMEA market size and forecast, by end user
7.5.4.Market size and forecast, by country

7.5.4.1.Brazil

7.5.4.1.1.Brazil Cardiovascular Diagnostic Testing market, by Type
7.5.4.1.2.Brazil Cardiovascular Diagnostic Testing market, by end user

7.5.4.2.Saudi Arabia

7.5.4.2.1.Saudi Arabia Cardiovascular Diagnostic Testing market, by Type
7.5.4.2.2.Saudi Arabia Cardiovascular Diagnostic Testing market, by end user

7.5.4.3.South Africa

7.5.4.3.1.South Africa Cardiovascular Diagnostic Testing market, by Type
7.5.4.3.2.South Africa Cardiovascular Diagnostic Testing market, by end user

7.5.4.4.Rest of LAMEA

7.5.4.4.1.Rest of LAMEA Cardiovascular Diagnostic Testing market, by Type
7.5.4.4.2.Rest of LAMEA Cardiovascular Diagnostic Testing market, by end user

CHAPTER 8:COMPANY PROFILES

8.1.ABBOTT LABORATORIES

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance

8.2.BECTON, DICKINSON AND COMPANY

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance

8.3.BIOMERIEUX, INC.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance

8.4.BIO-RAD LABORATORIES, INC.

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance

8.5.DANAHER CORPORATION

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance

8.6.F. HOFFMANN-LA ROCHE LTD.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance

8.7.PERKINELMER INC.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance

8.8.SIEMENS AG

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance

8.9.THERMO FISHER SCIENTIFIC, INC.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance

8.10.TOSOH CORPORATION

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance

LIST OF TABLES

TABLE 01.GLOBAL CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 02.CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR LABORATORY DEVELOPED TEST, BY REGION, 2020-2030 ($MILLION)
TABLE 03.CARDIOVASCULAR DIAGNOSTIC TESTING MARKET REVENUE FOR LABORATORY DEVELOPED TEST, BY TYPE 2020–2030 ($MILLION)
TABLE 04.CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR IN VITRO DIAGNOSTIC TEST, BY REGION, 2020-2030 ($MILLION)
TABLE 05.CARDIOVASCULAR DIAGNOSTIC TESTING MARKET REVENUE FOR IN VITRO DIAGNOSTIC TEST, BY TYPE 2020–2030 ($MILLION)
TABLE 06.CARDIO IQ REVENUE, 2020 (US$)
TABLE 07.CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 08.CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR LABORARTORY TESTING FACILITIES, BY REGION, 2020-2030 ($MILLION)
TABLE 09.CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR ACADEMIC INSTITUES, BY REGION, 2020-2030 ($MILLION)
TABLE 10.CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR POINT OF CARE TESTING (POCT) FACILITIES, BY REGION, 2020-2030 ($MILLION)
TABLE 11.CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 12.NORTH AMERICA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 13.NORTH AMERICA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 14.NORTH AMERICA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 15.U.S. CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 16.U.S. CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 17.CANADA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 18.CANADA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 19.MEXICO CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 20.MEXICO CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 21.EUROPE CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 22.EUROPE CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 23.EUROPE CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 24.GERMANY CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 25.GERMANY CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 26.FRANCE CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 27.FRANCE CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 28.UK CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 29.UK CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 30.ITALY CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 31.ITALY CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 32.SPAIN CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 33.SPAIN CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 34.REST OF EUROPE CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 35.REST OF EUROPE CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 36.ASIA-PACIFIC CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 37.ASIA-PACIFIC CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 38.ASIA-PACIFIC CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 39.JAPAN CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 40.JAPAN CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 41.CHINA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 42.CHINA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 43.INDIA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 44.INDIA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 45.AUSTRALIA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 46.AUSTRALIA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 47.SOUTH KOREA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 48.SOUTH KOREA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 49.REST OF ASIA-PACIFIC CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 50.REST OF ASIA-PACIFIC CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 51.LAMEA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 52.LAMEA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 53.LAMEA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 54.BRAZIL CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 55.BRAZIL CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 56.SAUDI ARABIA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 57.SAUDI ARABIA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 58.SOUTH AFRICA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 59.SOUTH AFRICA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 60.BRAZIL CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 61.REST OF LAMEA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 62.ABBOTT: COMPANY SNAPSHOT
TABLE 63.ABBOTT: OPERATING SEGMENTS
TABLE 64.ABBOTT: PRODUCT PORTFOLIO
TABLE 65.BD: COMPANY SNAPSHOT
TABLE 66.BD: OPERATING SEGMENTS
TABLE 67.BD: PRODUCT PORTFOLIO
TABLE 68.BIOMÉRIEUX, INC.: COMPANY SNAPSHOT
TABLE 69.BIOMÉRIEUX, INC.: OPERATING SEGMENTS
TABLE 70.BIOMÉRIEUX: PRODUCT PORTFOLIO
TABLE 71.BIO-RAD: COMPANY SNAPSHOT
TABLE 72.BIO-RAD: OPERATING SEGMENTS
TABLE 73.BIO RAD: PRODUCT PORTFOLIO
TABLE 74.DANAHER: COMPANY SNAPSHOT
TABLE 75.DANAHER: OPERATING SEGMENTS
TABLE 76.DANAHER: PRODUCT PORTFOLIO
TABLE 77.ROCHE: COMPANY SNAPSHOT
TABLE 78.ROCHE: OPERATING SEGMENTS
TABLE 79.ROCHE: PRODUCT PORTFOLIO
TABLE 80.PERKINELMER: COMPANY SNAPSHOT
TABLE 81.PERKINELMER: OPERATING SEGMENTS
TABLE 82.PERKINELMER PRODUCT PORTFOLIO
TABLE 83.SIEMENS: COMPANY SNAPSHOT
TABLE 84.SIEMENS: PRODUCT SEGMENTS
TABLE 85.SIEMENS: PRODUCT PORTFOLIO
TABLE 86.THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 87.THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 88.THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 89.TOSOH: COMPANY SNAPSHOT
TABLE 90.TOSOH: OPERATING SEGMENTS
TABLE 91.TOSOH: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.GLOBAL CARDIOVASCULAR DIAGNOSTIC TESTING MARKET SEGMENTATION
FIGURE 02.HIGH BARGAINING POWER OF BUYERS
FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 04.MODERATE THREAT OF SUBSTITUTION
FIGURE 05.MODERATE THREAT OF NEW ENTRANTS
FIGURE 06.MODERATE COMPETITVE RIVARLY
FIGURE 07.TOP INVESTMENT POCKETS, 2020
FIGURE 08.TOP PLAYER POSITIONING, 2020
FIGURE 09.IMPACT ANALYSIS
FIGURE 10.COMPARATIVE ANALYSIS OF CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR LABORATORY DEVELOPED TEST, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 11.LIPOPROTEIN TEST MARKET, 2020–2030 ($MILLION)
FIGURE 12.ANGIOTENSIN TEST MARKET, 2020–2030 ($MILLION)
FIGURE 13.FIBRINOGEN TEST MARKET, 2020–2030 ($MILLION)
FIGURE 14.SERUM URIC ACID TEST MARKET, 2020–2030 ($MILLION)
FIGURE 15.SERUM URIC ACID TEST MARKET, 2020–2030 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR IN VITRO DIAGNOSTIC TEST, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17.ELECTROCARDIOGRAM TEST MARKET, 2020–2030 ($MILLION)
FIGURE 18.ECHOCARDIOGRAPHY TEST MARKET, 2020–2030 ($MILLION)
FIGURE 19.TRANSESOPHAGEAL ECHOCARDIOGRAM TEST MARKET, 2020–2030 ($MILLION)
FIGURE 20.OTHER TEST MARKET, 2020–2030 ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22.COMPARATIVE ANALYSIS OF CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR ACADEMIC INSTITUES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR POINT OF CARE OF TESTING (POCT), BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 24.ABBOTT: NET SALES, 2018–2020 ($MILLION)
FIGURE 25.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 26.ABBOTT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 27.BD: NET SALES, 2018–2020 ($MILLION)
FIGURE 28.BD: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29.BD: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 30.BIOMÉRIEUX, INC.: REVENUE, 2018–2020 ($MILLION)
FIGURE 31.BIOMÉRIEUX: REVENUE SHARE BYSEGMENT, 2020 (%)
FIGURE 32.BIOMÉRIEUX: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 33.BIO-RAD: NET SALES, 2018–2020 ($MILLION)
FIGURE 34.BIO-RAD: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 35.BIO-RAD: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 36.DANAHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 37.DANAHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 38.DANAHER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 39.ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 40.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 41.ROCHE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 42.PERKINELMER: NET SALES, 2018–2020 ($MILLION)
FIGURE 43.PERKINELMER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 44.PERKINELMER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 45.SIEMENS: NET SALES, 2018–2020 ($MILLION)
FIGURE 46.SIEMENS: REVENUE SHARE BY PRODUCT SEGMENT, 2020 (%)
FIGURE 47.SIEMENS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 48.THERMO FISHER SCIENTIFIC: REVENUE, 2018–2020 ($MILLION)
FIGURE 49.THERMO FISHER SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 50.THERMO FISHER SCIENTIFIC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 51.TOSOH: NET SALES, 2018–2020 ($MILLION)
FIGURE 52.TOSOH: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 53.TOSOH: REVENUE SHARE BY REGION, 2020 (%)